CorMedix Inc.

CorMedix Inc. is a U.S.-based biopharmaceutical company that develops and commercializes therapies for serious, life-threatening conditions. Its core commercial product is DefenCath, an antimicrobial catheter lock solution used in hemodialysis patients, and in 2025 the company expanded through the acquisition of Melinta Therapeutics, adding a hospital-focused infectious disease portfolio and a cardiovascular brand.

48,4 %

88,5 %

52,3 %

+617,0 %

2.11

1.94

— CorMedix Inc.
%
DefenCath55% Commercial antimicrobial catheter lock solution sold in the U.S. dialysis market to reduce catheter-related bloodstream infections.
Melinta infectious disease portfolio35% Hospital- and clinic-focused anti-infective products used for gram-positive, gram-negative, and fungal infections.
TOPROL-XL5% Branded cardiovascular product with mature, limited-demand sales in a highly genericized beta-blocker class.
Contract and collaboration revenue5% BARDA and other licensing, milestone, royalty, and R&D service revenue tied to partnered programs.

CorMedix sells primarily to U.S. dialysis organizations, outpatient service providers, specialty distributors, and...

  • Dialysis organizationsprimary

    Buy DefenCath to reduce catheter-related bloodstream infections in chronic hemodialysis patients.

  • Hospital and acute care providersprimary

    Buy Melinta anti-infectives for inpatient and hospital-ecosystem treatment of serious infections.

  • Specialty distributorssecondary

    Distribute product into outpatient and hospital channels and support access to end customers.

  • Government and public health agenciessecondary

    Fund BARDA-supported development programs for pediatric and biothreat indications.

  • Cardiovascular prescribers and pharmaciessecondary

    Purchase TOPROL-XL where branded demand persists despite generic competition.

CorMedix is primarily a U.S. business, with DefenCath commercialized in the United States and most customers located...

  • •United States is the core commercial market for DefenCath and Melinta products
  • •U.S. dialysis centers are the main access point for DefenCath adoption
  • •Hospital, clinic, and home infusion channels are concentrated in the U.S.
  • •BARDA and licensing arrangements create non-product revenue exposure
  • •Foreign supplier reliance creates import and logistics exposure even if sales are U.S.-centric

CorMedix’s strategy is to maximize the value of its commercial portfolio by scaling DefenCath and using the Melinta...

01
Scale DefenCath commercializationshort-term

DefenCath is the largest contributor to net sales and the core growth driver.

02
Integrate and monetize the Melinta portfolioshort-term

The acquisition adds marketed products and a hospital-focused commercial platform.

03
Pursue label expansionsmedium-term

Additional indications can extend product lifecycles and broaden reimbursement access.

04
Add synergistic assets through business developmentmedium-term

New products can improve commercial leverage and reduce dependence on one asset.

CorMedix is exposed to customer concentration, reimbursement changes, and dependence on third-party manufacturers, all...

high

Customer concentration

A few customers account for a large share of revenue and can change purchasing with little notice.

Scope
Top three customers accounted for 79% of revenue in 2025.
Materiality
high
high

Reimbursement and pricing pressure

DefenCath economics depend on dialysis reimbursement dynamics and payer acceptance.

Scope
Transition from TDAPA to post-TDAPA add-on adjustment.
Materiality
high
high

Third-party manufacturing dependence

The company outsources all manufacturing and relies on single-source suppliers for some inputs.

Scope
Commercial supply, APIs, and logistics for all products.
Materiality
high
medium

Clinical and regulatory execution

Expanded indications require successful trials, filings, and FDA review.

Scope
DefenCath CLABSI and REZZAYO prophylaxis programs.
Materiality
medium
medium

Cybersecurity and third-party vendor disruption

Operations depend on cloud, CRO, CMO, logistics, and analytics vendors.

Scope
Manufacturing coordination, quality reporting, and commercial operations.
Materiality
medium
Revenue recognition and variable consideration
Can materially shift reported revenue and gross margin as estimates are updated
Returns reserve
Affects net sales and accrual balances; accrued returns were significant in 2025
Intangible asset amortization
Raises cost of revenues and depresses operating profitability
Acquisition accounting
Can affect future amortization, goodwill, and impairment risk
Lease accounting
Affects operating lease expense and balance sheet obligations

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

Corvex, Inc.

MOVE · Services-Computer Processing & Data Preparation

CORCEPT THERAPEUTICS INC

CORT · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

VERTEX PHARMACEUTICALS INC / MA

VRTX · Pharmaceutical Preparations

CONMED Corp

CNMD · Electromedical & Electrotherapeutic Apparatus

: 28.4.2026